Intravenous Vitamin C with Chemotherapy: Evidence, Protocols, and Practical Guidance for the Integrative Oncology Practitioner

Yoon Hang Kim, MD, MPH  •  Direct Integrative Care  •  March 2026

Introduction

Few topics in integrative oncology have endured as turbulent a history as high-dose intravenous vitamin C (IVC). Linus Pauling and Ewan Cameron’s case series in the 1970s suggested remarkable survival extensions in terminal cancer patients, only for two subsequent Mayo Clinic randomized trials to report no benefit. The critical distinction, however, was route of administration: Pauling and Cameron had used intravenous infusions, while the Mayo trials relied exclusively on oral dosing. We now understand that only intravenous delivery achieves the millimolar plasma concentrations—roughly 10 to 30 mM—required for pharmacologic, pro-oxidant activity against malignant cells. Oral vitamin C, no matter how high the dose, plateaus in the low micromolar range due to saturable intestinal absorption.

The mechanistic rationale is increasingly well characterized. At pharmacologic concentrations, ascorbate generates hydrogen peroxide selectively in the extracellular fluid of the tumor microenvironment, exploiting the low catalase activity typical of many cancer cells. Normal tissues, equipped with robust catalase and peroxidase defenses, remain largely unaffected. Additional pathways under investigation include modulation of hypoxia-inducible factor-1α, epigenetic regulation through effects on TET dioxygenases and Jumonji-C domain demethylases, enhancement of immune surveillance, and reduction of systemic oxidative stress biomarkers such as F₂-isoprostanes.

After decades of preclinical groundwork—much of it originating from Dr. Mark Levine’s group at the National Institutes of Health and the University of Iowa—the clinical evidence has now matured to a point that demands serious attention from integrative and conventional practitioners alike. This article synthesizes the available trial data, safety considerations, dosing protocols, and practical scheduling guidance to inform clinical decision-making when co-administering IVC with cytotoxic chemotherapy.

The Evidence Base: From Case Reports to Phase II Trials

The modern clinical investigation of IVC in oncology can be organized into three waves of progressively rigorous evidence.

Early Case Series and the Oral–Intravenous Clarification

Cameron and Pauling’s original reports from Vale of Leven Hospital in Scotland described prolonged survival in 100 terminal cancer patients given 10 g of ascorbate daily, initially intravenously and then orally. When the Mayo Clinic attempted replication using oral vitamin C alone, no survival advantage emerged. For more than two decades, this apparent negative result suppressed academic interest in ascorbate as a cancer therapy. The pharmacokinetic work of Padayatty, Levine, and colleagues at the NIH ultimately resolved the discrepancy: intravenous administration bypasses intestinal absorption limits and achieves plasma levels 100- to 500-fold higher than any achievable oral dose, entering the pharmacologic range where pro-oxidant anticancer activity becomes possible.

Phase I–II Combination Trials

Hoffer and colleagues at the Jewish General Hospital in Montreal published a pivotal phase I–II trial in 2015, enrolling 14 patients with refractory advanced solid tumors receiving various standard chemotherapy regimens alongside IVC at 1.5 g/kg body weight, administered two to three times weekly (PLoS One 2015;10:e0120228). The trial demonstrated acceptable safety and tolerability, with only transient adverse events—nausea, thirst, and mild venous irritation—reported during or after infusions. No clinically significant increases in urinary oxalic acid were observed. Pharmacokinetic analysis suggested that tissue uptake of vitamin C may actually increase following chemotherapy, an observation with potentially important implications for optimal scheduling. Three patients experienced unexpected transient stable disease, increased energy, and functional improvement.

In ovarian cancer, Ma and colleagues conducted a randomized trial of paclitaxel and carboplatin with or without IVC (75–100 g twice weekly for 12 months) in 25 patients with stage III–IV disease (Sci Transl Med 2014;6:222ra18). The IVC group experienced significantly fewer grade 1–2 chemotherapy-related toxicities—including neurotoxicity, bone marrow suppression, gastrointestinal symptoms, and infections—without worsening of grade 3–4 adverse events. A trend toward improved overall survival and a progression-free survival advantage of approximately 8.75 months favoring the IVC arm were also observed, though the trial was not powered to detect survival differences as a primary endpoint.

The University of Iowa Pancreatic Cancer Landmark

The most compelling data to date emerged from the University of Iowa. Bodeker, Cullen, and colleagues published a randomized phase 2 trial in Redox Biology (2024;77:103375) enrolling 34 patients with stage IV metastatic pancreatic ductal adenocarcinoma. Patients were randomized 1:1 to standard chemotherapy with gemcitabine and nab-paclitaxel alone, or the same regimen plus infusions of 75 g pharmacological ascorbate three times weekly. The results were striking: median overall survival in the IVC-plus-chemotherapy arm was 16 months, compared with 8.3 months in the chemotherapy-alone arm (HR 0.46; 90% CI 0.23–0.92; p = 0.030). Median progression-free survival also improved, from 3.9 to 6.2 months (HR 0.43; p = 0.029). Notably, the addition of IVC did not increase the frequency or severity of adverse events and did not compromise quality of life—in fact, patients in the IVC arm appeared to tolerate higher cumulative doses of chemotherapy for longer durations.

The trial was terminated early due to the strength of the survival signal, which exceeded the investigators’ prespecified threshold of clinical significance. Dr. Cullen has noted that the Iowa team’s earlier phase 1 trial combining IVC with radiation for unresectable pancreatic cancer produced three patients who remain alive more than nine years after diagnosis—far beyond the expected survival for that disease. These results have generated significant interest in a definitive multicenter phase III trial, though funding remains a challenge given that ascorbic acid is an unpatentable, low-cost compound.

Additional Tumor Types and Ongoing Investigation

The Iowa group has also completed a phase 2 trial in glioblastoma multiforme, published in Clinical Cancer Research in early 2024, demonstrating a five-month survival extension when IVC was added to temozolomide and radiation. A phase 2 trial in non-small-cell lung cancer is nearing completion. Meanwhile, a large Chinese randomized trial (Wang et al., n = 442) evaluating IVC with FOLFOX-based chemotherapy in metastatic colorectal cancer has added further safety data, confirming that physician-assessed adverse events in the IVC arm were comparable to the control group. Across these heterogeneous settings, a consistent theme emerges: IVC appears remarkably well tolerated and may reduce certain chemotherapy-associated toxicities while preserving or enhancing antitumor efficacy.

Safety, Screening, and Contraindications

The safety profile of properly screened, properly administered high-dose IVC is well established across hundreds of treated patients in prospective trials. Serious adverse events are rare. However, certain clinical scenarios demand rigorous exclusion or dose limitation.

Universal Pre-Treatment Screening

Before initiating IVC in any patient, the following baseline evaluations are essential. Glucose-6-phosphate dehydrogenase (G6PD) activity must be measured, as G6PD-deficient individuals are at risk for potentially severe hemolytic anemia when exposed to the pro-oxidant load generated by pharmacologic ascorbate. Renal function must be assessed with serum creatinine, estimated glomerular filtration rate, and urinalysis; a history of nephrolithiasis or oxaluria should be specifically elicited, given the theoretical risk of calcium oxalate stone formation with high-dose ascorbate. Iron and copper storage diseases—hemochromatosis and Wilson disease—constitute relative contraindications due to the potential for ascorbate to enhance Fenton chemistry in the setting of excess free metal ions. A complete metabolic panel, complete blood count, ferritin, iron studies, and inflammatory markers (CRP, ESR) round out the recommended baseline laboratory evaluation. In high-risk patients, 24-hour urinary oxalate measurement may be warranted.

Absolute and Relative Contraindications

High-dose IVC (generally defined as exceeding 75 g per infusion or achieving plasma concentrations above 10 mM) should be avoided in patients with significant renal failure, anuria, severe dehydration, severe pulmonary edema, or low cardiac output states. A history of oxalate nephropathy or recurrent calcium oxalate nephrolithiasis is an absolute contraindication to high-dose protocols. Pregnancy and lactation warrant caution, as clinical data in these populations are sparse. These screening and exclusion criteria are endorsed by the Riordan IVC protocol framework, the NCI’s Physician Data Query summary, and multiple published trial eligibility criteria.

Common and Expected Adverse Effects

In appropriately screened patients, the most frequently reported side effects of IVC are transient and mild: nausea, headache, thirst, chills, and local venous irritation at the infusion site. These effects are typically manageable with adequate pre-infusion hydration and appropriate infusion rates (90–120 minutes for a full-dose infusion). Temporary polyuria in the first 24 hours following infusion is expected and reflects the osmotic diuretic properties of concentrated ascorbate. In patients with compromised cardiac function, the volume load of the carrier solution (approximately 20 mL of normal saline per gram of vitamin C) must be accounted for to avoid transient volume overload.

Scheduling IVC Around Chemotherapy

One of the most common questions in clinical practice concerns the optimal timing of IVC relative to cytotoxic drug administration. The pharmacokinetic profile of IVC provides a practical framework: following intravenous infusion, plasma ascorbate levels peak at roughly 10–30 mM, with a half-life of approximately two hours and a return to baseline within about four hours.

Regimens with Published Combination Data

For chemotherapy agents that have been formally co-administered with IVC in published trials—including gemcitabine, nab-paclitaxel, erlotinib, paclitaxel, and carboplatin—the existing data support a “bookending” strategy: IVC is typically given the day before chemotherapy and again one to two days after chemotherapy, two to three times per week. In the Iowa pancreatic cancer trial, 75 g infusions were administered three times weekly alongside gemcitabine and nab-paclitaxel cycles. In the Hoffer trial, IVC was given on days bracketing chemotherapy (for example, day −1 and day +2 relative to the chemotherapy infusion). None of these trials reported evidence of pharmacokinetic antagonism or reduced chemotherapy efficacy.

Regimens Without Published Combination Data

For chemotherapy regimens that have not been specifically studied in combination with IVC, a more conservative approach is prudent. One widely cited expert recommendation is to separate the IVC infusion from the cytotoxic agent by at least five half-lives of the chemotherapy drug, ensuring that the cytotoxic agent has been substantially cleared before introducing the pro-oxidant ascorbate load. In practice, this generally translates to giving IVC the day before or the day after chemotherapy rather than on the same day. IVC should not be administered concurrently through the same intravenous line during active cytotoxic infusion, and it should not be combined with investigational agents without explicit oncologist approval and careful consideration of potential reactive oxygen species interactions.

Dosing Protocols: A Synthesis from Published Trials

Test Dose and Titration

A conservative approach begins with an initial test dose of 15–25 g IVC infused over 60–90 minutes, with monitoring of blood pressure, heart rate, symptom response, and post-infusion metabolic panel as indicated. If the test dose is well tolerated and no laboratory red flags emerge (rising creatinine, hyperkalemia, hemolysis markers), the dose is escalated over one to three additional infusions toward the intended target. The titration schedule depends on clinical goals.

Supportive Care Dosing

When the primary objectives are symptom relief, quality of life improvement, and reduction of chemotherapy-associated toxicities, doses of 25–75 g per infusion administered one to three times weekly represent the range most commonly reported in supportive care literature. This dosing range has demonstrated improvements in global health scores, appetite, sleep quality, mood, and fatigue across several small controlled and uncontrolled studies.

Cytotoxic-Intent Dosing (Experimental)

When the goal extends to potential direct antitumor activity, the published trial protocols utilize higher doses in the range of 0.8–1.5 g/kg body weight per infusion (typically 50–100 g for most patients), administered two to three times weekly. This is the dosing range employed in the Hoffer trial (1.5 g/kg), the Iowa pancreatic cancer trial (75 g), and the Ma ovarian cancer trial (75–100 g). These protocols require rigorous renal monitoring and careful patient selection, and should be understood as investigational.

Duration of Treatment

The Hoffer protocol specified a minimum of two months of treatment, with continuation in cases of disease stability or response and re-evaluation every two months. In the Ma ovarian cancer trial, IVC was continued for a full 12 months alongside chemotherapy. Clinical judgment, disease trajectory, patient tolerance, and ongoing renal function guide the decision to continue, pause, or discontinue IVC infusions.

Clinical Protocol Summary

The following table consolidates practical parameters from published trials into a reference template for individualization in clinical practice.

Documented Clinical Benefits

Across the available trial data, several categories of benefit have been reported with varying degrees of evidence strength. The most consistently demonstrated benefit is reduction in chemotherapy-associated toxicities: neurotoxicity, fatigue, gastrointestinal distress, infections, and myelosuppression were all reduced in the ovarian cancer trial when IVC was added to paclitaxel and carboplatin. Quality of life improvements—encompassing global health, appetite, sleep, and mood—have been reported in multiple settings, though many of these observations come from uncontrolled or small studies.

The survival data from Iowa are the most provocative finding in the field. A doubling of median overall survival in metastatic pancreatic cancer—from 8.3 to 16 months—in a randomized trial is a result that exceeds the incremental improvements seen with most novel systemic agents in this disease. The finding that patients in the IVC arm tolerated higher cumulative chemotherapy doses for longer periods suggests a potential synergistic mechanism that warrants further investigation. The five-month survival extension in glioblastoma further supports the hypothesis that pharmacologic ascorbate may enhance the therapeutic index of standard treatment across multiple tumor types.

Limitations and Guideline Positions

Intellectual honesty requires acknowledging what the evidence does not yet prove. No definitive phase III randomized controlled trial has been completed for IVC in any tumor type. The Iowa pancreatic trial, while randomized and remarkably compelling, enrolled only 34 patients at a single institution. The NCI currently classifies high-dose IVC as a complementary or investigational therapy, citing insufficient large-scale trial data for incorporation into standard oncologic practice. MD Anderson Cancer Center cautions that the evidence remains inconsistent and generally recommends IVC use in the context of clinical trials or closely coordinated integrative care.

Practitioners should clearly communicate to patients that IVC is not a proven curative therapy, that it should never replace or delay standard chemotherapy, and that its most established role at present is as a supportive care adjunct with emerging but preliminary evidence of direct antitumor benefit. The absence of pharmaceutical industry interest in funding large trials—attributable to the unpatentable nature of ascorbic acid—represents a structural barrier to generating the definitive evidence that the field requires. Until multicenter phase III data become available, clinical use of IVC with chemotherapy should reflect careful individualization, oncology collaboration, thorough informed consent, and rigorous monitoring.

Conclusion

High-dose intravenous vitamin C represents a biologically plausible, pharmacologically distinct, and increasingly evidence-supported adjunct to cytotoxic chemotherapy. Its primary established roles are symptom control, quality of life improvement, and reduction of treatment-related toxicities. The landmark University of Iowa pancreatic cancer trial has added a powerful survival signal that may ultimately reshape integrative oncology practice if confirmed in larger, multi-institutional studies. Optimal clinical use demands rigorous patient screening, careful timing around chemotherapy, collaborative communication with the treating oncology team, and transparent discussion with patients about the investigational nature of the therapy. For practitioners committed to evidence-informed integrative cancer care, IVC is no longer a fringe curiosity—it is a therapeutic tool that merits serious, careful, and humble engagement.

Selected References

Bodeker KL, Smith BJ, Berg DJ, et al. A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Redox Biology. 2024;77:103375.

Hoffer LJ, Robitaille L, Zakarian R, et al. High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I–II clinical trial. PLoS One. 2015;10(4):e0120228.

Ma Y, Chapman J, Levine M, et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014;6(222):222ra18.

Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004;140(7):533–537.

Chen Q, Espey MG, Sun AY, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA. 2008;105(32):11105–11109.

Wang F, He MM, Wang ZX, et al. Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer. BMC Cancer. 2019;19(1):460.

National Cancer Institute. Intravenous Vitamin C (PDQ®)—Health Professional Version. Accessed March 2026.

Fritz H, Flower G, Weeks L, et al. Intravenous vitamin C and cancer: a systematic review. Integr Cancer Ther. 2014;13(4):280–300.

Ngo B, Van Riper JM, Cantley LC, Yun J. Targeting cancer vulnerabilities with high-dose vitamin C. Nat Rev Cancer. 2019;19(5):271–282.

About the Author

Yoon Hang Kim, MD, MPH, is a board-certified physician in Preventive Medicine and Integrative & Holistic Medicine. He is a Certified Medical Acupuncturist (UCLA), Osher Fellow (University of Arizona), and IFM Scholar. He practices at Direct Integrative Care and Hill Country Integrative Medicine in Fredericksburg, Texas.